Fund moves
109 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 26, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 26, 2026 · Filed Jan 28, 2026
The CEO of Johnson & Johnson sold $11.3M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$11,318,461
Shares × reported transaction price
5 days after results of Jan 21, 2026, 78 days before results of Apr 14, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $221.49 on Jan 26, 2026, at its 52-week high, after a 7% rise over the previous 30 trading days
52-week range $146.36 (May 14, 2025) to $221.49 (Jan 26, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $206.54 on Dec 10, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Darzalex Faspro on Jan 27, 2026, 1 day after this trade.
New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.6% | −2.4% | +7.0% |
| 30 days | +9.4% | −1.1% | +10.5% |
| 90 days | 0.0% | +2.5% | −2.5% |
| 180 days | +17.4% | +6.8% | +10.6% |
Past results only. Not a forecast.
Fund moves
109 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 26, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Feb 20 · filed 3 days laterNot reported under a pre-arranged trading plan
Johnson & Johnson's WW Chair, MedTech sold $325K of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Feb 13 · filed 6 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.